The Southampton Dupuytren's Scoring Scheme

Mohan, Anita T.; Vadher, Jane; Ismail, Hiba; Warwick, David

doi:10.3109/2000656x.2013.794349

Cited by 38 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An example that has been shown to be sufficiently sensitive to change is the Boston questionnaire for carpal tunnel syndrome [118]. Recently the Unité Rhumatologique de Affections de la Main scale (URAM) questionnaire [15] and Southampton Dupuytren’s Scoring System [119] have been developed as disease specific questionnaires, but have not yet been validated by other investigators.…”

Section: Discussionmentioning

confidence: 99%

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Ball

Pratt

Nanchahal

2013

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundDupuytren's disease of the hand is a common condition affecting the palmar fascia, resulting in progressive flexion deformities of the digits and hence limitation of hand function. The optimal treatment remains unclear as outcomes studies have used a variety of measures for assessment.MethodsA literature search was performed for all publications describing surgical treatment, percutaneous needle aponeurotomy or collagenase injection for primary or recurrent Dupuytren’s disease where outcomes had been monitored using functional measures.ResultsNinety-one studies met the inclusion criteria. Twenty-two studies reported outcomes using patient reported outcome measures (PROMs) ranging from validated questionnaires to self-reported measures for return to work and self-rated disability. The Disability of Arm, Shoulder and Hand (DASH) score was the most utilised patient-reported function measure (n=11). Patient satisfaction was reported by eighteen studies but no single method was used consistently. Range of movement was the most frequent physical measure and was reported in all 91 studies. However, the methods of measurement and reporting varied, with seventeen different techniques being used. Other physical measures included grip and pinch strength and sensibility, again with variations in measurement protocols. The mean follow-up time ranged from 2 weeks to 17 years.ConclusionsThere is little consistency in the reporting of outcomes for interventions in patients with Dupuytren’s disease, making it impossible to compare the efficacy of different treatment modalities. Although there are limitations to the existing generic patient reported outcomes measures, a combination of these together with a disease-specific questionnaire, and physical measures of active and passive individual joint Range of movement (ROM), grip and sensibility using standardised protocols should be used for future outcomes studies. As Dupuytren’s disease tends to recur following treatment as well as extend to involve other areas of the hand, follow-up times should be standardised and designed to capture both short and long term outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Ball

Pratt

Nanchahal

2013

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…33 The functional score chosen for this study (SDSS) was a diseasespecific, patient-related outcome measure with good inter-observer reliability and better sensitivity than Quick-DASH (Disability of the arm, shoulder and hand). 31 Our participants reported a significant improvement in functional score (8.24 versus 1.88 P ≤ 0.0005) between initial and 30 days review and this improvement persisted at 12 months with a score of 1.59 (P ≤ 0.0005).…”

Section: Discussionmentioning

confidence: 56%

“…31 Adverse events recorded were those which arose from first injection until 4 weeks. The SDSS is a disease-specific, patient-related outcome measure with good internal consistency.…”

Section: Efficacy Endpoints and Assessmentsmentioning

confidence: 99%

See 1 more Smart Citation

Collagenase injections for Dupuytren's contracture: prospective cohort study in a public health setting

Fletcher

Tan

Thomas

et al. 2019

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background: Dupuytren's disease causes a flexion contracture of the hand that limits hand function and reduces quality of life. Traditional management is surgical excision which is associated with potentially serious complications. A viable alternative is collagenase Clostridium histolyticum (CCH) (Xiaflex ® ; Pfizer Australia) which is an effective, safe, outpatient treatment that to date has no published data in the Australian public health setting. Methods: A prospective cohort, single centre study, enrolling 54 patients to treat 81 joints with CCH. Patients received a single dose to the cord followed by joint manipulation 48 h later. Primary endpoint was reduction in contracture to 0 to 5 of full extension assessed 4 weeks after injection. Secondary endpoints included range of motion, patient satisfaction and function as measured by the Southampton Dupuytren's Scoring Scheme (SDSS). Results: Primary endpoint was achieved in 48% of joints (66% metacarpophalangeal and 19% proximal interphalangeal). Mean flexion contracture improved by 40 o and 25 o for metacarpophalangeal and proximal interphalangeal joints, respectively. Mean active range of motion improved by 39 o and 18 o , respectively. At 30 days and 12 months, SDSS score demonstrated sustained improvement versus baseline (1.88 versus 8.24 P ≤ 0.0005 and 1.59 versus 8.07 P ≤ 0.0005). Sixty-eight percent of patients were either very satisfied or satisfied at 12-month follow-up. Side effects of treatment were minor; with oedema and bruising the most common (87% and 85%, respectively). Conclusion: CCH injections are a viable treatment for Dupuytren's contracture in the Australian public health setting.

show abstract

“…Our results serve to show that QuickDASH is not the most effective tool for assessment of DD outcomes. Several authors [17,21] advocate the use of disease-specific questionnaires, such as the Southampton Dupuytren's Scoring System (SDSS) [22] or the Unité Rhumatologique des Affections de la Main (URAM) [23,24], moving away from employing more widely used questionnaires for the measurement of DD outcomes, such as DASH or Michigan Hand Outcomes, since pain is among the parameters the latter assess, which is rare in DD, and they also do not show proper correlation with improvement in the range of finger movement.…”

Section: Discussionmentioning

confidence: 99%

Usefulness of the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire in Dupuytren's Disease: A Prospective Cohort Study

Herrero¹,

Sanjuán-Cerveró²,

Alonso³

et al. 2019

Arch Med

View full text Add to dashboard Cite

Background: Dupuytren's Disease (DD) is a fibroproliferative disease which affects the hands and can produce progressive and irreversible flexion contractures. Collagenase Clostridium histolyticum (CCH) is a minimallyinvasive treatment option for it. Hand function and patient´s satisfaction were commonly measured by the Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire. The Spanish QuickDASH is the only validated Spanish region-specific questionnaire can be employed for the clinical assessment of patients with pathologies of the hand, such as Dupuytren's Disease. The aim of the study was to determine the usefulness of the abbreviated Spanish version of the QuickDASH, as an effective tool for evaluation of Dupuytren's disease treatment outcomes and their correlation with objective outcomes measuring improvement in residual contracture following treatment. Methods: We conducted a prospective cohort study from April 2016 to June 2017 involving the selection of patients from three different hospitals. The measurement of the clinical results was made by calculating the difference between prior and post-treatment degrees of contraction (Thomine´s coefficient) and QuickDASH questionnaire was self-administered by patients pre-and post-treatment. Results: 46 patients (66.1 ± 1.1 years) completed the study. The mean correction for the metacarpophalangeal joint was-26.67 degrees (p<0.001) and-23.39 degrees for the proximal interphalangeal joint. The mean change in QuickDASH score was 8.88 (p<0.001) at a mean 34.6-day follow-up. The study showed a low correlation between the QuickDASH scores and the improvement in mobility, showing a weak relation between the scores (r<0.2). Conclusion: In our study, QuickDASH questionnaire scores for the treatment of Dupuytren´s disease did not correlate with clinical outcomes.

show abstract

The Southampton Dupuytren's Scoring Scheme

Cited by 38 publications

References 15 publications

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Collagenase injections for Dupuytren's contracture: prospective cohort study in a public health setting

Usefulness of the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire in Dupuytren's Disease: A Prospective Cohort Study

Contact Info

Product

Resources

About